(PTGX) |
| 0 (0%) 07-16 15:29 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 164.80 |
| Resistance 1: | 141.10 |
| Pivot price: | 130.44 |
| Support 1: | 118.72 |
| Support 2: | 104.89 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -1.730 |
| Book Value | 10.210 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.152 |
| Profit Margin (%) | -154.88 |
| Operating Margin (%) | -6.47 |
| Return on Assets (ttm) | -12.4 |
| Return on Equity (ttm) | -17.1 |
Company news
Wed, 15 Jul 2026
Protagonist Therapeutics Jumps 5.3% After Barclays Maintains Overweight - AlphaStreet
Tue, 14 Jul 2026
PTGX Maintained by Barclays -- Price Target Raised to $151 - GuruFocus
Sat, 11 Jul 2026
Protagonist Therapeutics (PTGX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Sat, 11 Jul 2026
Protagonist Therapeutics (PTGX) Investor Update Summary - Quartr
Fri, 10 Jul 2026
Will Icotyde’s Launch and Rusfertide’s Priority Review Change Protagonist Therapeutics’ (PTGX) Narrative - simplywall.st
Thu, 09 Jul 2026
Protagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority Review - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
